🫀 TAVR or SAVR? The 7-Year Truth   New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.   🔎 Highlights • Composite events: 34.6% (TAVR) vs 37.2% (SAVR) • Mortality: 19.5% vs 16.8% • Valve failure: 6.9% vs 7.3% • Aortic gradients remain low in both groups   💡 Clinical rhythm: less AF with TAVR; more pacemakers and paravalvular leak.   This study reinforces a simple truth: in the right low-risk patient, TAVR is not just less invasive — it's durable.   #Cardiology #StructuralHeart #AorticStenosis #TAVR #SAVR #NEJM

Ver todos los episodios